paroxetine has been researched along with Cardiomyopathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Glumac, S; Japundžić-Žigon, N; Kosić, M; Nešić, Z; Pajović, V; Savić, B; Vasić, M | 1 |
| MacIver, DH; Partridge, SJ; Solanki, T | 1 |
2 other study(ies) available for paroxetine and Cardiomyopathies
| Article | Year |
|---|---|
Paroxetine mitigates cardiac remodelling by doxorubicin and increases survival.
Topics: Animals; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiotonic Agents; Cardiotoxicity; Doxorubicin; Gene Expression Regulation; Male; Paroxetine; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Ventricular Remodeling | 2022 |
A depressed myocardium.
Topics: Adult; Anti-Arrhythmia Agents; Cardiomyopathies; Chest Pain; Cyclohexanols; Electrocardiography; Heart; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Tachycardia, Sinus; Venlafaxine Hydrochloride; Ventricular Function, Left | 2000 |